The global short bowel syndrome market is consolidated. Shire Plc.
held 50% of the market in 2015. Strategic acquisitions have become a
strategy for key players. The players are also focused on marketing
over-the-counter dietary supplements over-the-counter dietary
supplements as well as manufacturing these supplements. Companies are
also focusing on developing Innovative Therapies which Focus majorly
on gastrointestinal diseases, states Transparency Market Research in
its latest research on the global short bowel syndrome market. Names
of the key players operating in the market are: Shire plc, Emmaus
Life Sciences, Inc., Merck KGaA, and Nutrinia Ltd, OxThera, GlyPharma
Therapeutics, Ardelyx, Inc., Sancilio & Company, Inc., Zealand
Pharma A/S, and Naia Pharmaceuticals.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13346
According to the research report, the global short bowel syndrome
(SBS) market is expected to be worth US$2.6 bn by the end of 2024 and
expand at a whopping CAGR of 30.4%. in the period from 2016 to 2024.
On the basis of geography, North America is expected to exhibit at
32.7% CAGR from 2016 to 2024 and lead in the short bowel syndrome
Market. In terms of drug class, the global short bowel syndrome
market is expected to be led by the GLP-2 drug leaving behind
glutamine and growth hormones. The GLP-2 drug is expected to expand
at a whopping 36% CAGR between 2016 and 2024. This drug is sold both
in the US and in the Europe under the brand name Gattex and Revestive
respectively. Due to its exclusivity, GLP-2 drug is anticipated to
contribute considerably to the revenues of the short bowel syndrome
market worldwide.
According to the lead author of this report, parenteral nutrition is
extremely costly and is administered to the patient which allows into
steins to maintain homeostasis and adapts to the changes and this
unaffordability of parenteral nutrition will bolster the demand for
short bowel syndrome drugs which reduce the patient's dependence on
parenteral nutrition. The growing incidences of short bowel syndrome
is expected to drive the growth of this market. The additional
assistance offered to patients suffering from short bowel syndrome
through Gattex is also aiding the growth of the market. The increase
in consumption of unhealthy and junk food, sedentary lifestyle, and
busy lifestyle with no time to focus on nutritious and healthy food
are some of the other factors that will help this market to grow
further.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=13346
Awareness Programs by Several Foundations Driving Growth
Prospects
However, there are many challenges which this Market face, one of
them being the Rarity of this disease on account of which the
diagnosis rate is relatively low. In addition to this, the approved
drugs of short bowel syndrome is not available easily all across the
world. However, this also results in a significant pool of patients
with unmet medical needs which will create a potential for growth in
future. Another factor drive the growth prospects of this Market is
increasing focus and investment by several foundations and
associations in creating a heightened awareness level about short
bowel syndrome. As of now, the National Organization for rare
disorders along with its member organizations such as the Oley
Foundation, the short bowel syndrome Foundation, the Association of
gastrointestinal motility, and the SBS Cure Project are creating
awareness about short bowel syndrome among the people. Apart from
these organizations, drug manufacturers are also raising awareness
programs all these factors are helping the market to grow.
Numerous Dangerous Side Effects Restricts Demand
A key factor which is expected to restrict the growth of this Market
is the side effects of taking drugs that help in the treatment of
short bowel syndrome. The most common effects on the health by
Revestive or Gattex include cold, nausea, flu, abdominal pain, and
headaches. In addition to this it has been found that these medicines
can further cause complications in the body such as blockage of the
bowel, abnormal cell growth which could for the lead to cancer,
polyps in the colon, and inflammation of the gallbladder or blockage
of the pancreas. Another challenge which is facing the market is the
non-availability of the approved drugs in developing nations
especially.
Request for the TOC of the Report @
https://www.transparencymarketresearch.com/report-toc/13346
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
